Matthew S. Davids

ORCID: 0000-0003-4529-2003

Also affiliated with Dana-Farber Cancer Institute

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile

0.518Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Blood Advances(2024)10.1182/bloodadvances.2023011574

Top 37%

0.518DataRank

Top 37%12 citations

Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker +18 more

Papers

Driven by 46 papers — median percentile 63. Top paper: “Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study”.

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00455-1

N/A

3.3DataRank · unranked

104 citations

Benjamin L. Lampson, Svitlana Tyekucheva, Zixu Wang, Jessica Lowney, Samantha Pazienza +13 more

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

Blood(2020)10.1182/blood.2019004710

N/A

2.8DataRank · unranked

99 citations

Haesook T. Kim, Caitlin Costello, Alex F. Herrera, Frederick L. Locke, Rodrigo Maegawa +20 more

Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

Nature Medicine(2023)10.1038/s41591-022-02113-6

N/A

1.7DataRank · unranked

83 citations

Ignaty Leshchiner, Romain Guièze, Connor Johnson, Eugen Tausch, Sameer A. Parikh +49 more

Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0276

N/A

1.5DataRank · unranked

64 citations

Satyen H. Gohil, Caleb A. Lareau, Leif S. Ludwig, Erin M. Parry, Teddy Huang +15 more

Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.10.010

N/A

0.618DataRank · unranked

17 citations

Robert Redd, Erin Jeter, Jeff L. Wong, Kristin M McHugh, Carol Reynolds +21 more

An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL

Blood Advances(2024)10.1182/bloodadvances.2023012142

N/A

0.569DataRank · unranked

18 citations

John N. Allan, Dan James, Helen Bridge, Miguel Miranda, Alan SM Yong +6 more

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Blood Advances(2024)10.1182/bloodadvances.2023011574

Top 37%

0.518DataRank

Top 37%12 citations

Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker +18 more

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Blood Advances(2024)10.1182/bloodadvances.2024014633

N/A

0.420DataRank · unranked

9 citations

Danielle M. Brander, Yesid Alvarado, Catherine Diefenbach, Daniel Nathan Egan, Shira Dinner +14 more

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Blood Neoplasia(2025)10.1016/j.bneo.2025.100108

N/A

0.173DataRank · unranked

2 citations

Rachel J. Cook, Shira Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi‐Sharifi +9 more

SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7512

N/A

0.165DataRank · unranked

2 citations

Inhye E. Ahn, Svitlana Tyekucheva, Reid W. Merryman, David C. Fisher, Philippe Armand +7 more

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

Haematologica(2021)10.3324/haematol.2020.271304

N/A

0DataRank · unranked

9 citations

Charles Herbaux, Bernd Boidol, Chantal Guillemette, Patrick Caron, Marius Mayerhöfer +17 more

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance

Blood Advances(2022)10.1182/bloodadvances.2022008447

N/A

0DataRank · unranked

80 citations

Filippo Utro, Qing Wang, Justin Cha, Mauno Vihinen, Stephen P. Martindale +20 more

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies

Journal of Clinical Investigation(2023)10.1172/jci170169

N/A

0DataRank · unranked

43 citations

Fen Zhu, Olga Dashevsky, Rin Mizuno, Jolin Xiao Hui Lai, Liam Hackett +19 more

Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax

Haematologica(2023)10.3324/haematol.2023.283245

N/A

0DataRank · unranked

14 citations

Jennifer L. Crombie, Wei Ni, Nguyet-Minh Hoang, Swati Garg, Liam Hackett +6 more

Overcoming Resistance in Chronic Lymphocytic Leukemia—Maybe Less Is More?

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2872

N/A

0DataRank · unranked

9 citations

Matthew S. Davids, Othman Al‐Sawaf

Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors

Blood Cancer Journal(2023)10.1038/s41408-023-00788-9

N/A

0DataRank · unranked

3 citations

Stephen P. Martindale, Pui Yan Chiu, Jasneet Kaur Khalsa, Pei-Hsuan Chen, Stacey M. Fernandes +10 more

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.11.14.566994

N/A

0DataRank · unranked

4 citations

Eugenio Gaudio, Sara Napoli, Charles Herbaux, Chiara Tarantelli, Roberta Bordone +15 more

Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.08.01.551480

N/A

0DataRank · unranked

2 citations

Elizabeth D. Lightbody, Mairéad Reidy, Junko Tsuji, Michelle P. Aranha, Daniel Heilpern-Mallory +15 more

Targeted engagement of β-catenin-Ikaros complexes in refractory B-cell malignancies

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.13.532152

N/A

0DataRank · unranked

1 citations

Huda Jumaa, Mark E. Robinson, Klaus M. Kistner, Liang Xu, Gang Xiao +18 more

Data from Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History

(2023)10.1158/2159-8290.c.6549383.v1

N/A

0DataRank · unranked

0 citations

Satyen H. Gohil, Caleb A. Lareau, Leif S. Ludwig, Erin M. Parry, Teddy Huang +15 more

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Blood(2023)10.1182/blood-2023-173992

N/A

0DataRank · unranked

0 citations

Ted Gooley, Tanya Siddiqi, Deborah M. Stephens, Catherine M. Broome, Stephen E. Spurgeon +18 more

PI3K Inhibitors in Hematology: When One Door Closes…

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0967

N/A

0DataRank · unranked

23 citations

Klaus Okkenhaug, Matthew S. Davids, Sigrid S. Skånland

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

Blood Advances(2024)10.1182/bloodadvances.2023011307

N/A

0DataRank · unranked

18 citations

Jeff P. Sharman, Paolo Ghia, Jennifer A. Woyach, Toby A. Eyre, Wojciech Jurczak +7 more

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas

Blood Advances(2024)10.1182/bloodadvances.2023012291

N/A

0DataRank · unranked

8 citations

Sara Napoli, Eugenio Gaudio, Charles Herbaux, Eleonora Cannas, Chiara Tarantelli +16 more

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Blood Neoplasia(2024)10.1016/j.bneo.2024.100047

N/A

0DataRank · unranked

6 citations

Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui +6 more

Therapeutic targeting of apoptosis in chronic lymphocytic leukemia

Seminars in Hematology(2024)10.1053/j.seminhematol.2024.01.015

N/A

0DataRank · unranked

7 citations

Matthew S. Davids, Inhye E. Ahn

Investigating the influence of germline ATM variants in chronic lymphocytic leukemia on cancer vulnerability

Haematologica(2024)10.3324/haematol.2024.286031

N/A

0DataRank · unranked

3 citations

Francesca Morelli, Kiyomi Mashima, Rayan Fardoun, Svitlana Tyekucheva, Stacey M. Fernandes +7 more

Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis

American Journal of Hematology(2024)10.1002/ajh.27421

N/A

0DataRank · unranked

0 citations

Teresa González, Miguel Quijada Álamo, Gian Matteo Rigolin, Adrian M. Dubuc, Ángela Villaverde Ramiro +15 more

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition

Journal of Hematology & Oncology(2025)10.1186/s13045-024-01634-6

N/A

0DataRank · unranked

131 citations

Hannah Lau, Lukas M. Carter, E. Hui Clarissa Lee, Hiu Yan Lam, Elena Okina +34 more

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Blood(2025)10.1182/blood.2024028064

N/A

0DataRank · unranked

16 citations

Monia Marchetti, Othman Al‐Sawaf, Ohad Benjamini, Alexey V. Danilov, Matthew S. Davids +24 more

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025016006

N/A

0DataRank · unranked

12 citations

Yinglu Zhou, Mariia Mikhaleva, Daniel Choi, Stacey M. Fernandes, Philippe Armand +20 more

Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies

Leukemia(2025)10.1038/s41375-025-02694-4

N/A

0DataRank · unranked

8 citations

Jolin Xiao Hui Lai, Kartini Iskandar, Benedict J. Leong, Chuqi Wang, Yuhan Wang +10 more

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL

Blood Cancer Journal(2025)10.1038/s41408-025-01236-6

N/A

0DataRank · unranked

12 citations

Ying Huang, Sarah Miller, John N. Allan, Seema A. Bhat, David A. Bond +40 more

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee

Blood Cancer Journal(2025)10.1038/s41408-025-01341-6

N/A

0DataRank · unranked

3 citations

Inhye E. Ahn, Aswin Sekar, Andy C. Rawstron, Júlia Almeida, José Ignacio Martin-Subero +18 more

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation

Hematological Oncology(2025)10.1002/hon.70064

N/A

0DataRank · unranked

2 citations

Matthew S. Davids, Nathalie Javidi‐Sharifi

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Blood(2020)10.1182/blood.2020006965

N/A

0DataRank · unranked

318 citations

Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori A. Leslie, John M. Pagel +57 more

Long‐term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia

HemaSphere(2025)10.1002/hem3.70067

N/A

0DataRank · unranked

0 citations

Yue Ren, Svitlana Tyekucheva, Jon Arnason, Adam Boruchov, Caron A. Jacobson +6 more

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Blood Advances(2020)10.1182/bloodadvances.2020001956

N/A

0DataRank · unranked

86 citations

Peter Dreger, Jennifer R. Brown, Oscar Lahoud, Toby A. Eyre, Danielle M. Brander +20 more

BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1427

N/A

0DataRank · unranked

50 citations

Lindsey E. Roeker, Mazyar Shadman, Matthew S. Davids, Stephen J. Schuster, Anthony R. Mato +1 more

Management of CLL patients early in the COVID‐19 pandemic: An international survey of CLL experts

American Journal of Hematology(2020)10.1002/ajh.25851

N/A

0DataRank · unranked

21 citations

Anthony R. Mato, John C. Byrd, Alexey V. Danilov, Brad Hedrick, Chaitra S. Ujjani +6 more

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses

American Journal of Hematology(2020)10.1002/ajh.26084

N/A

0DataRank · unranked

29 citations

Sarah R. Walker, Lisa N. Heppler, Svitlana Tyekucheva, Erik A. Nelson, Josephine L. Klitgaard +15 more

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade

Haematologica(2020)10.3324/haematol.2020.258426

N/A

0DataRank · unranked

5 citations

Adam S. Sperling, Christopher J. Gibson, Olga Pozdnyakova, Waihay J. Wong, Michael P. Manos +5 more

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

UNC Libraries(2020)10.17615/mbvm-5959

N/A

0DataRank · unranked

0 citations

Bruce D. Cheson, Matthew S. Davids, Kristie A. Blum, Sonali M. Smith, Steven I. Park +10 more

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Blood(2021)10.1182/blood.2021011841

N/A

0DataRank · unranked

70 citations

Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff, Matthew S. Davids +47 more

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Blood(2021)10.1182/blood.2021010867

N/A

0DataRank · unranked

42 citations

Yi Zhang, Alexandra Savell, Teddy Huang, Nicoletta Cieri, Emily M. Thrash +33 more

A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia

Leukemia(2021)10.1038/s41375-021-01441-9

N/A

0DataRank · unranked

21 citations

Alec Griffith, Svitlana Tyekucheva, Zixu Wang, Vanessa Rai, Alexander R. Vartanov +14 more

Matthew S. Davids

Indexed papers

Top data-sharing exemplar

Papers